Stephanie has growth hormone deficiency

Growth disorders/growth hormone

Our ambition

We created the world’s first liquid, pre-mixed human growth hormone delivered in a dedicated pen system, Norditropin® SimpleXx®.

Novo Nordisk has been a major player in the field of growth hormone therapy for many decades, and we have world-class expertise in the physiology and pathophysiology of growth and regeneration. We hold a leading position in the global growth hormone market, aiming for a leadership position – and we keep exploring new modalities to treat human growth hormone disorders.

Our partnering focus

We seek technologies and compounds:

  • With long-acting potential
  • Suitable for oral administration

Read more about Biopharmaceuticals Research Unit

Contact us

For further information, please contact Jørn Müller 


Download partnering for innovation brochure


Where to meet us

We are attending events all over the world to meet with new potential partners.

Event calendar